Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord 2017;32:1701-1709.

Oertel, W, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, et al. 2017. “Randomized, Placebo-Controlled Trial of ADS-5102 (amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 3). Mov Disord 2017;32:1701-1709.”. Mov Disord.

Last updated on 10/02/2024